ATE469653T1 - Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit - Google Patents

Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit

Info

Publication number
ATE469653T1
ATE469653T1 AT05787236T AT05787236T ATE469653T1 AT E469653 T1 ATE469653 T1 AT E469653T1 AT 05787236 T AT05787236 T AT 05787236T AT 05787236 T AT05787236 T AT 05787236T AT E469653 T1 ATE469653 T1 AT E469653T1
Authority
AT
Austria
Prior art keywords
obesity
hydrate
disease
treatment
taste receptor
Prior art date
Application number
AT05787236T
Other languages
English (en)
Inventor
Soraya Shirazi-Beechey
Jane Dyer
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Application granted granted Critical
Publication of ATE469653T1 publication Critical patent/ATE469653T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT05787236T 2004-09-22 2005-09-22 Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit ATE469653T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04077610 2004-09-22
PCT/EP2005/054760 WO2006032693A1 (en) 2004-09-22 2005-09-22 Intestinal epithelial glucose sensor

Publications (1)

Publication Number Publication Date
ATE469653T1 true ATE469653T1 (de) 2010-06-15

Family

ID=35457669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05787236T ATE469653T1 (de) 2004-09-22 2005-09-22 Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit

Country Status (7)

Country Link
US (1) US20090196878A1 (de)
EP (1) EP1802324B1 (de)
AT (1) ATE469653T1 (de)
AU (1) AU2005286494B2 (de)
CA (1) CA2577632C (de)
DE (1) DE602005021667D1 (de)
WO (1) WO2006032693A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
WO2009046168A1 (en) 2007-10-02 2009-04-09 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
GB201804816D0 (en) * 2018-03-26 2018-05-09 Anglia Ruskin Univ Higher Education Corporation Cancer treatment
JP2023546022A (ja) 2020-10-08 2023-11-01 ジーバイオティクス カンパニー 腸内での繊維合成酵素の発現のための操作されたプロバイオティクス

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642240A (en) * 1982-09-30 1987-02-10 General Foods Corporation Foodstuffs containing 3-aminobenzesulfonic acid as a sweetener inhibitor
GB8309855D0 (en) * 1983-04-12 1983-05-18 Tate & Lyle Plc Flavour modifiers
US4544565A (en) * 1984-03-29 1985-10-01 General Foods Corporation Foodstuffs containing sweetness inhibiting agents
US4910031A (en) * 1988-12-19 1990-03-20 Frito-Lay, Inc. Topped savory snack foods
JPH07184548A (ja) * 1993-12-28 1995-07-25 Meiji Seito Kk 口腔用組成物
US7803982B2 (en) * 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
FR2825236B1 (fr) * 2001-05-30 2004-10-15 Lmd Composition orale comprenant un extrait d'ecorce d'albissia myriophylla et son utilisation pour supprimer ou reduire la fonction gustative
US7115284B2 (en) * 2003-08-11 2006-10-03 Ayurvedic-Life International, Llc Compositions for diabetes treatment and prophylaxis
US20050244810A1 (en) * 2003-09-29 2005-11-03 Egan Josephine M Taste signaling in gastrointestinal cells
WO2005116069A2 (en) * 2004-04-14 2005-12-08 Monell Chemical Senses Center Taste receptors of the t1r family from domestic dog
US20090170949A1 (en) * 2006-01-25 2009-07-02 Soraya Shirazi-Beechey Method To Control Body Weight

Also Published As

Publication number Publication date
AU2005286494A1 (en) 2006-03-30
WO2006032693A1 (en) 2006-03-30
CA2577632A1 (en) 2006-03-30
CA2577632C (en) 2014-04-01
EP1802324A1 (de) 2007-07-04
EP1802324B1 (de) 2010-06-02
DE602005021667D1 (de) 2010-07-15
US20090196878A1 (en) 2009-08-06
AU2005286494B2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
MA32872B1 (fr) Traitement du diabete chez des patients dont la regulation glycemique est insuffisante malgre une therapie par un medicament antidiabetique oralou non oral
WO2008008286A3 (en) Substituted pyrazoles as ghrelin receptor antagonists
ZA200807986B (en) Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
EA201100266A1 (ru) Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
EP2217596B8 (de) Bicyclische heterocyclische derivate und ihre verwendung als modulatoren der aktivität von gpr 119
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
MY153198A (en) Inhibitors of protein aggregation
DE602004009295D1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
MX2009003658A (es) Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
GB0222495D0 (en) Compounds
ATE552031T1 (de) Pharmazeutische zusammensetzungen enthaltend nicht-acyliertes ghrelin zur behandlung von insulinresistenz
TW200635878A (en) Hydroxybiphenylcarboxylic acids and derivatives, processes for preparing them and their use
MY137477A (en) Substituted oxazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
ATE484506T1 (de) Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use
Bartolozzi The natural approach to osteoporosis
DE602005021667D1 (de) Inhibitoren der geschmacksrezeptoren zur verwendung in der behandlung von fettleibigkeit und zuckerkrankheit
ATE526023T1 (de) Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
WO2005115446A3 (en) Detection and use of prolylcarboxypeptidase
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
TW200513197A (en) Amino acid supplementation for a healthy microbiota ecosystem
EP1882474A4 (de) Prophylaktisches/therapeutisches mittel für abweichungen im zucker/fettstoffwechsel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties